INTELLIGENT BIO SOLUTIONS INC. (INBS)
About INTELLIGENT BIO SOLUTIONS INC.
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company operates through new reportable segments: United Kingdom; Asia Pacific (APAC); Americas; and Rest of World, of which United Kingdom derives maximum revenue.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $3.1M
- Net income
- -$10.6M
- Total assets
- $8.2M
- Market cap
- $5.9M
- Gross margin
- 40.8%
- Operating margin
- -348.7%
- Net margin
- -347.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $3.1M
- Cost of revenue
- $1.8M
- Gross profit
- $1.2M
- Operating expenses
- $12.7M
- Operating income
- -$10.6M
- Net income
- -$10.6M
- EPS (basic)
- $-2.00
- EPS (diluted)
- $-2.00
Balance sheet
- Total assets
- $8.2M
- Current assets
- $4.1M
- Total liabilities
- $5.4M
- Current liabilities
- $5.4M
- Shareholders’ equity
- $2.8M
Cash flow
- Operating cash flow
- -$9.7M
- Investing cash flow
- -$231.8K
- Financing cash flow
- $4.6M
- Net cash flow
- -$5.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $5.9M
- EPS (diluted)
- $-2.0
- Shares outstanding
- 3.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 23, 2020
Intelligent BIO Solutions Inc. (INBS) Stock Price
- Reported a net loss of $10.6M in FY2025.
- Revenue grew 187% from FY2023 to FY2025.
- Gross margin of 40.8%, net margin -347.4%.
- Trading 92% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review INTELLIGENT BIO SOLUTIONS INC..
Write a review
News about INTELLIGENT BIO SOLUTIONS INC.
News & sentiment via Polygon.io
Intelligent BIO Solutions Inc.: frequently asked questions
Is Intelligent BIO Solutions Inc. an American company?
Intelligent BIO Solutions Inc. is a US-based company headquartered in New York, New York, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Intelligent BIO Solutions Inc. headquartered?
Intelligent BIO Solutions Inc. is headquartered in New York, New York, United States.
Is Intelligent BIO Solutions Inc. publicly traded?
Yes — Intelligent BIO Solutions Inc. is a publicly traded company. Its stock trades under the ticker symbol INBS on the NASDAQ.
What does Intelligent BIO Solutions Inc. do?
Intelligent BIO Solutions Inc. is an American Medical Devices company in the Health & Beauty sector.
